STOCK TITAN

Cytek Biosciences, Inc. - $CTKB STOCK NEWS

Welcome to our dedicated page for Cytek Biosciences news (Ticker: $CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytek Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytek Biosciences's position in the market.

Rhea-AI Summary
Cytek Biosciences to participate in Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
-
Rhea-AI Summary
Cytek Biosciences appoints Philippe Busque as SVP of Global Sales & Services, enhances sales organization and creates a new platform organization. Acquisition of Amnis and Guava product lines provides expanded market access and new product development opportunities. Chief Commercial Officer Todd Garland is leaving for another opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
management
-
Rhea-AI Summary
Cytek Biosciences to participate in UBS MedTech, Tools and Genomics Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences earnings
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) will be participating in the 44th Annual Goldman Sachs Healthcare Conference. The company's management will be in a fireside chat on June 14th at 3:20 p.m. PT / 6:20 p.m. ET. The presentation can be accessed live or archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
conferences
Rhea-AI Summary
Cytek Biosciences announces approval of $50 million stock repurchase program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
buyback
-
Rhea-AI Summary
Cytek Biosciences ships its 100th Cytek Aurora CS system, showcasing the demand for its Full Spectrum Profiling™ technology. The Aurora CS offers high-sensitivity capabilities at the single-cell level and allows for easy transfer of assays from analyzer to sorter without redesigning panels or reconfiguring detector systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.04%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
conferences earnings
Cytek Biosciences, Inc.

Nasdaq:CTKB

CTKB Rankings

CTKB Stock Data

827.02M
105.71M
8.71%
65.33%
7.6%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
FREMONT

About CTKB

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.